COMPOSITION FOR TREATING AUTOIMMUNE HEMOLYTIC ANEMIA

PURPOSE:To obtain the subject multiple drug-resistant and safe composition, comprising carbamoyl-beta-D-ribofuranosyl-imidazolium-oleate as an active ingredient, capable of rapidly improving symptoms and reducing the weight of a steroidal agent used in combination and having low toxicity. CONSTITUTI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	MORIMOTO IPPEI
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PURPOSE:To obtain the subject multiple drug-resistant and safe composition, comprising carbamoyl-beta-D-ribofuranosyl-imidazolium-oleate as an active ingredient, capable of rapidly improving symptoms and reducing the weight of a steroidal agent used in combination and having low toxicity. CONSTITUTION:This composition comprises 4-carbamoyl-1-beta-D- ribofuranosylimidazolium-5-oleate (generic name: mizoribine) as an active ingredient. A commercially available pharmaceutical preparation of the mizoribine for oral administration is preferably simply used as the composition. The composition is preferably administered in a daily dose of 100-300mg at a time in 2-3 divided portions to an adult patient weighing 50-60kg by using a 25-mg or a 50-mg tablet of the pharmaceutical preparation of the mizoribine for the oral administration.